NVL-655
- Generic Name
- NVL-655
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
NVL-655 is an orally bioavailable, brain-penetrant anaplastic lymphoma kinase (ALK) inhibitor inhibitor being investigated for the treatment of non-small cell lung cancer.
- Associated Conditions
- -
- Associated Therapies
- -
NVL-655 for TKI-naive Patients With Advanced ALK-Positive NSCLC
Phase 3
Not yet recruiting
- Conditions
- Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positive
- Interventions
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT06765109
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath